PO-1182: PSMA-PET is superior to choline-PET based SABR for ADT deferral in oligometastatic prostate cancer. (November 2020) - Deijen, C.; Vrijenhoek, G.; Vogel, W.; Moonen, L.; Pos, F.; Van der Poel, H.; Borst, G.